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A paper in this issue of Chemistry & Biology shows that the diaryl oxazole compound UA62784 that targets
pancreatic cancer cells interacts with tubulin near the colchicine binding site (Tcherniuk et al., 2011). These
findings differ from previous observations, highlighting the challenges of identifying the biological target for
chemical inhibitors.Cancer is linked to abnormal cell prolifer-
ation and differentiation and this loss of
regulation induces escape from senes-
cence and death. The main cytotoxic
agents are classified into four categories:
(1) DNA alkylating agents, (2) inhibitors of
topoisomerases I and II, (3) antimetabolite
agents, and (4) microtubule targeting
agents (MTAs). The latter are also called
antimitotics and are known to interact
with tubulin at four main binding sites:
the taxane/epothilone, laulimalide, colchi-
cine, and vinca alkaloid sites (Figure 1).
Binding to taxane and laulimalide sites
stabilizes microtubules, whereas binding
to the others induces tubulin depoly-
merization. These microtubule-targeting
agents perturb not only mitosis but also
cellular trafficking during interphase.
MTAs induce microtubule polymerization
or depolymerization at high concentra-
tions, while low doses kinetically stabilize
microtubules without changing their poly-
mer mass (Jordan and Wilson, 2004). The
success of antimitotics is overshadowed
by the occurrence of resistance owing
to a number of different factors. For
example, resistance can occur due to
the overexpression of the P-glycoprotein,
an ABC transporter involved in the efflux
of antineoplastic drugs from cancer cells
(Sandor et al., 1998), or tubulin mutations
at the drug binding site (Mozzetti et al.,
2008). Other cytoskeletal proteins (g-actin
and actin-regulating proteins), as well as
variations in tubulin isotypes or microtu-
bule-associated proteins expression,
can also regulate the pool of microtubules
and disturb the activity of MTAs (Kavalla-
ris, 2010). In addition, the success of
MTAs, which is usually attributed to the
induction of mitotic arrest, is counterbal-anced by deleterious side effects owing
to essential microtubule functions beyond
mitosis. This led to the development of
new compounds that inhibit cellular
targets with exclusive mitotic functions.
These proteins include Aurora kinases,
kinesin spindle protein (KSP), polo-like
kinases 1 (PLK1), and the centromeric
protein E (Cenp-E), which are only active
during mitosis where they are responsible
for controlling different steps in the
assembly and function of the mitotic
spindle (Jackson et al., 2007). Aurora
kinases control the spindle checkpoint
and cytokinesis, whereas KSP is respon-
sible for establishing mitotic spindle
bipolarity. PLK1 regulates centrosome
maturation and formation of the mitotic
spindle and Cenp-E is involved in chro-
mosome congression. Agents that disrupt
mitosis have, however, shown only limited
clinical input to date (Komlodi-Pasztor
et al., 2011), so the screening for new
compounds is still in progress.
Two recent studies (Henderson et al.,
2009 and Tcherniuk et al., this issue)
reported the characterization of a new di-
aryl oxazole compound, UA62784, which
selectively targets pancreatic cancer
cells. This compound showed remarkable
activity in both studies, providing new
hope for the treatment of this extremely
aggressive neoplasia. However, the
proposed mechanism of action differs in
the two studies. Henderson et al. attrib-
uted UA62784 effects to a direct inhibition
of Cenp-E ATPase activity, whereas
Tcherniuk et al. now show that UA62784
promotes microtubule depolymerization
by binding to microtubules near the
colchicine binding site. In brief, Hender-
son et al. observed that UA62784 had noChemistry & Biology 18, May 27, 2011effect on tubulin polymerization, but found
that UA62784 inhibits Cenp-E ATPase
activity, without affecting Cenp-E ability
to bind microtubules or BubR1 at the
kinetochore, which are critical for Cenp-
E function. Interestingly, it shouldbenoted
that a related study showed that only
a couple of the UA62784 derivatives,
produced as a part of an extensive SAR
exploration, inhibited Cenp-E while the
majority had no inhibitory effect on
Cenp-E or other kinesins tested (Shaw
et al., 2009), leading the authors to
conclude that UA62784 derivatives did
not reproduceUA62784Cenp-E inhibitory
ability. The same study showed that
UA62784 derivatives inhibited a subset
of kinases, suggesting a possible alterna-
tive mechanism of antitumor action. This
example of potentially incorrect conclu-
sion, i.e., UA62784 inhibits Cenp-E
activity, is not unprecedented since other
cases can be found in the literature. For
example, anthracyclines were classified
as DNA-interacting agents but later were
found to damage cellular components
including cancer cells membranes, via
multiple cellular targets (Komlodi-Pasztor
et al., 2011).
Tcherniuk et al.’s study now adds
another layer of insight into the UA62784
mechanism of action. The authors use
biophysical binding studies coupled
with in vivo imaging fluorescence data, to
provide evidence that UA62784 interacts
with tubulin with nanomolar affinity.
Binding studieswereperformed in solution
with microtubules that had been polymer-
ized frompurified tubulin andprovide valu-
able information regarding the kinetics of
microtubule dynamics and the interaction
of UA62784 with microtubules. Based onª2011 Elsevier Ltd All rights reserved 555
Figure 1. Targets of Chemotherapy for Cell Cycle Perturbation
(A) Tubulin binding sites of antimicrotubule agents. Taxanes preferentially bind to the tubulin subunit of polymeric microtubule at the lumen of the microtubule
pore. Epothilones bind the same site as taxanes, but exploit the tubulin-binding pocket in a unique and independent manner. Laulimalide binds at a site that
is distinct from the paclitaxel/epothilone site. Colchicine and relatedmolecules that bind at the same site inducemicrotubule depolymerization by inhibiting lateral
contacts between microtubule protofilaments, but they have a better affinity for free tubulin heterodimers. Vinca alkaloids preferential bind free tubulin, but also
bind microtubule ends.
(B) Progression of mitosis through the canonical morphological stages. Specific druggable protein targets that function during mitosis are highlighted.
Kinesin spindle protein (KSP) is required to establish mitotic spindle bipolarity by driving centrosome separation. Centromeric protein E is required for accurate
chromosome congression at metaphase. Aurora A is crucial for centrosome maturation and separation during early prophase. Aurora B is involved in chromo-
somal alignment on the metaphase plate, bipolar kinetochore-microtubule attachments, spindle checkpoint, and cytokinesis. During mitosis, Polo-like kinase 1
(PLK1) is involved in centrosome maturation and formation of the mitotic spindle. PLK1 is also required for exit from mitosis and the separation of sister
chromatids during anaphase. PLK1 might also have a role in cytokinesis through the phosphorylation of the kinesin-like motor protein MKLP1. Reprinted
from Jackson et al. (2007) Nat. Rev. Cancer 7, 107–117, with permission from Macmillan Publishers Ltd., copyright 2007.
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biophysical analysis, Tcherniuk et al.
concluded that UA62784 could provide
a better treatment strategy at lower doses
due to UA62784 higher binding affinity for
tubulin, when compared with other well-
known antimicrotubule agents, such as
vinblastine.556 Chemistry & Biology 18, May 27, 2011 ªFrom the discussion above, it is clear
that probing theexact spatial relationships
between proteins and drugs requires the
use of investigation tools that can be
applied at molecular level, such as optical
tweezers (Calligaris et al., 2010). Alterna-
tively, molecular mass spectrometry (MS)
imaging has recently emerged as a prom-2011 Elsevier Ltd All rights reservedising tool to address the challenge of
drug-target colocalization. This sensitive
technique allows rapid and quantitative
profiling of drugs in tissues without
any prior knowledge and avoids the
use of antibodies. Mass spectrometry
imaging is therefore more powerful in this
regard than classical immunochemistry;
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tivity are limited. Numerous matrix-assis-
ted laser desorption/ionization (MALDI)
MS imaging studies have reported
biomarker identification for prognosis of
lung and brain cancers, and also for eluci-
dating disease mechanisms (McDonnell
et al., 2010). In cytoskeleton research,
MALDI imaging has been used to locate
the interaction of unlabeled small mole-
cules with microtubules.
In conclusion, studies that examine
effects of smallmolecules and aim to iden-
tify their specific cellular targets need
to include specific cellular readouts at
the molecular level together with a com-
plementary set of in vivo and in vitro
techniques for their unambiguous valida-tion, thus focusing basic and clinical
research on the right targets and avoiding
erroneous conclusions and unfounded
claims.REFERENCES
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2-Oxoglutarate oxygenases (2-OGs) are a large enzyme family involved in numerous processes in health and
disease. Rotili et al. (2011) describe in this issue of Chemistry & Biology an activity-based protein profiling-
based strategy with which the activity of individual members of the 2-OG family can be addressed in the
context of complex biological systems.Activity-based protein profiling (ABPP)
has emerged as a powerful strategy in
chemical biology research involving
enzymes (Evans and Cravatt, 2006). In
ABPP research, activity-based probes
(ABPs) are designed to recognize, and
subsequently bind covalently to, an
enzyme or enzyme family, preferably in
complex biological systems. An ABP is
normally assembled from three individual
functional parts: a recognition element
(generally but not necessarily derived
from the substrate of the enzyme at
hand), a reactive group (for instance,
electrophilic trap, photoreactive group),
and an affinity tag. ABPP studies on
enzymes are complementary to classical
enzyme inhibition studies, in which anisolated enzyme reacts with a fluorogenic
substrate, either in the presence or
absence of a competitive inhibitor.
Inhibition constants can be accurately
measured in this fashion, which provides
valuable information in case the inhibitor
at hand is considered as a lead for drug
development.
The kinetics studies of covalent, irre-
versible inhibitors are considerably more
complicated. For this reason, andperhaps
more importantly also for the widespread
belief in medicinal chemistry that such
compoundswouldmake poor drug candi-
dates, covalent inhibitors have been ne-
glected for some time. This situation
changed drastically a decade ago with
a number of seminal studies. Biotinylatedbroad-spectrum inhibitors of serine hy-
drolases (Liu et al., 1999) and cysteine
proteases (Greenbaum et al., 2000)
proved highly useful in the profiling of
these hydrolytic enzymes in cell extracts
and living cells. At the same time, biotiny-
lation of the natural product epoxomicin
led to the identification of proteasomes
as the target of this toxic, but potentially
therapeutic, agent (Meng et al., 1999).
These groundbreaking studies have
opened the field of ABPP, and several
attractive aspects of the strategy have
been addressed in the following years.
As said, transforming a natural product
into an ABP may reveal its biomolecular
target. Enzyme activities may be un-
earthed, or the presence (or absence) ofª2011 Elsevier Ltd All rights reserved 557
